title: The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
abstract: Because some aldose reductase inhibitor studies have demonstrated clinical improvement in scored neurological signs and symptoms of diabetic neuropathy, a prospective study of the effect on cardiovascular performance of sorbinil 250 mg/day for 12 months was conducted on patients with diabetic autonomic neuropathy who were free of atherosclerotic coronary artery disease and/or cardiomyopathy. After 1 year of treatment, the study group (n = 14) demonstrated significant improvement in both the resting cardiac output (P = 0.02), and the maximal cardiac output (P = 0.03). This observation suggests that the use of an aldose reductase inhibitor may be useful in treating suboptimal cardiovascular performance in patients with diabetic cardiac autonomic neuropathy.
authors.affiliation: Diabetic Research Unit, Louisville Veterans Administration Medical Center, KY.
authors.forename: T M
authors.initials: TM
authors.lastname: Roy
authors.forename: V L
authors.initials: VL
authors.lastname: Broadstone
authors.forename: H R
authors.initials: HR
authors.lastname: Peterson
authors.forename: H L
authors.initials: HL
authors.lastname: Snider
authors.forename: J
authors.initials: J
authors.lastname: Cyrus
authors.forename: R
authors.initials: R
authors.lastname: Fell
authors.forename: A H
authors.initials: AH
authors.lastname: Rothchild
authors.forename: E
authors.initials: E
authors.lastname: Samols
authors.forename: M A
authors.initials: MA
authors.lastname: Pfeifer
mesh_terms: D000328:Adult; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D004837:Epinephrine / Q000097:blood; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D048289:Imidazolidines; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000188:drug therapy / Q000503:physiopathology; D009638:Norepinephrine / Q000097:blood; D011446:Prospective Studies
chemical_list: D007093:Imidazoles; D048289:Imidazolidines; D000449:Aldehyde Reductase; C026411:sorbinil; D009638:Norepinephrine; D004837:Epinephrine